Results 221 to 230 of about 218,870 (301)

Design, Synthesis, and Biological Evaluation of Methoxy-Substituted Chalcones and Gypsogenin-Based Hybrids as Anticancer and Antimicrobial Agents. [PDF]

ACS Omega
Ulusoy NG, Emirdağ S, Kahriman N, Demir F, Serdaroğlu V, Yaylı N, Türkmenoğlu B.   +6 more
europepmc   +1 more source

Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single‐Institution Cohort Study

Head &Neck, EarlyView.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is a rare malignancy with a propensity for perineural invasion and hematogenous spread. Central nervous system (CNS) involvement is uncommon, and detailed clinical and genomic data on this aspect of the disease remain limited.
Omar Elghawy, Jack Stylli, Martin Kurian, Eitan Halper‐Stromberg, Aditi Singh, Christopher D'Avella, Lee Hartner, Roger B. Cohen   +7 more
wiley   +1 more source

A systematic assessment of the short- and long-term effects of commonly used breast cancer chemotherapeutics on the gut microbiome‒blood‒brain axis of female mice. [PDF]

Gut Microbes
Valentine YA, Duff AF, Bailey MT, Pyter LM.   +3 more
europepmc   +1 more source

Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer. [PDF]

Biomater Res
Lameirinhas A, Díez P, Hicke FJ, Ágreda-Roca A, Torres-Ruiz S, Sánchez-Serrano P, Tapia M, Lluch A, Bermejo B, Cejalvo JM, Martínez-Máñez R, Eroles P, Garrido-Cano I.   +12 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Doxorubicin induces ferroptosis in endometrial cancer by suppressing the MKK6/p38/CEBPB axis. [PDF]

J Transl Med
Zhang J, Wang Z, Li Y, Zhao P, Ren D, Lu X.   +5 more
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

The Synthesis and Anticancer Activity of the Trastuzumab-Doxorubicin Antibody-Drug Conjugate Using Strain-Promoted Alkyne-Azide Coupling. [PDF]

ACS Omega
Thakur SK, Ghosh R, Chauhan N, Guchhait P, Eswaran SV.   +4 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source